Department of Urology, Medical University of Vienna, Vienna, Austria; Division of Urology, Department of Special Surgery, Jordan University Hospital, The University of Jordan, Amman, Jordan.
Urology Service, Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, NY, USA.
Eur Urol. 2018 Apr;73(4):543-557. doi: 10.1016/j.eururo.2017.09.030. Epub 2017 Nov 7.
The role of surgery in metastatic bladder cancer (BCa) is unclear.
In this collaborative review article, we reviewed the contemporary literature on the surgical management of metastatic BCa and factors associated with outcomes to support the development of clinical guidelines as well as informed clinical decision-making.
A systematic search of English language literature using PubMed-Medline and Scopus from 1999 to 2016 was performed.
The beneficial role of consolidation surgery in metastatic BCa is still unproven. In patients with clinically evident lymph node metastasis, data suggest a survival advantage for patients undergoing postchemotherapy radical cystectomy with lymphadenectomy, especially in those with measurable response to chemotherapy (CHT). Intraoperatively identified enlarged pelvic lymph nodes should be removed. Anecdotal reports of resection of pulmonary metastasis as part of multimodal approach suggest possible improved survival in well-selected patients. Cytoreductive radical cystectomy as local treatment has also been explored in patients with metastatic disease, although its benefits remain to be assessed.
Consolidative extirpative surgery may be considered in patients with clinically evident pelvic or retroperitoneal lymph nodal metastases but only if they have had a response to CHT. Surgery for limited pulmonary metastases may also be considered in very selected cases. Best candidates are those with resectable disease who demonstrate measurable response to CHT with good performance status. In the absence of data from prospective randomized studies, each patient should be evaluated on an individual basis and decisions made together with the patient and multidisciplinary teams.
Surgical resection of metastases is technically feasible and can be safely performed. It may help improve cancer control and eventually survival in very selected patients with limited metastatic burden. In a patient who is motivated to receive chemotherapy and to undergo extirpative surgical intervention, surgery should be discussed with the patient among other consolidation therapies in the setting of multidisciplinary teams.
手术在转移性膀胱癌(BCa)中的作用尚不清楚。
在这篇合作综述文章中,我们回顾了有关转移性 BCa 手术治疗的当代文献以及与结局相关的因素,以支持临床指南的制定和知情的临床决策。
使用 PubMed-Medline 和 Scopus 从 1999 年到 2016 年进行了英语文献的系统搜索。
巩固性手术在转移性 BCa 中的有益作用仍未得到证实。在有临床明显淋巴结转移的患者中,数据表明接受化疗后根治性膀胱切除术加淋巴结切除术的患者有生存优势,特别是在对化疗有可测量反应的患者中。应切除术中发现的增大的盆腔淋巴结。作为多模式治疗一部分切除肺转移的偶然报告表明,在精选的患者中可能改善生存。作为局部治疗的细胞减灭性根治性膀胱切除术也已在转移性疾病患者中进行了探索,尽管其益处仍有待评估。
如果患者对 CHT 有反应,临床上有明显的骨盆或腹膜后淋巴结转移,可考虑进行巩固性切除术。在非常特定的情况下,也可考虑对有限的肺转移灶进行手术。最佳候选者是那些有可切除疾病的患者,这些患者对 CHT 有可测量的反应且表现出良好的体能状态。在缺乏前瞻性随机研究数据的情况下,应根据每位患者的具体情况进行评估,并与患者和多学科团队一起做出决策。
转移性病灶的外科切除在技术上是可行的,并且可以安全进行。在极少数转移负担有限的患者中,它可能有助于改善癌症控制并最终提高生存率。对于有动机接受化疗并接受根治性手术干预的患者,应在多学科团队的背景下与患者讨论手术作为其他巩固性治疗之一。